On November 20, DexCom fell 4.04% in Regular Trading, trading near $79.225 per share, with turnover of $149 million.
The clearest recent catalyst was a disclosed insider transaction: the company reported that Executive Vice President and Chief Legal Compliance Officer Michael Jon Brown sold 1,700 common shares on November 16 at $83.46 per share, for proceeds of about $141,882.
The filing showed Brown still directly held 95,034 shares after the sale. While DexCom previously reported third-quarter results above expectations, including adjusted EPS of $0.73 on revenue of $1.344 billion and raised full-year revenue guidance to $5.20 billion-$5.25 billion, the latest trading appears more immediately tied to short-term pressure from the executive sale disclosure rather than operating fundamentals.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments